Relay Therapeutics exec sells shares after option exercise
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Relay Therapeutics, Inc. reported that President, R&D Donald A. Bergstrom exercised options for 93,456 shares of common stock at $4.12 per share and sold 93,456 shares at a weighted average price of $16.94 per share in multiple trades ranging from $16.15 to $17.39, pursuant to a Rule 10b5-1 trading plan adopted on October 30, 2025.
After these transactions, he directly holds 418,557 shares of common stock, including 15,037 shares underlying restricted stock units. The exercised option, which was fully vested and had an expiration date of April 9, 2028, now has no remaining balance.
Insider Trade Summary 10b5-1
Exercise and Sale: 93,456 shares ($1.20M approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Bergstrom Donald A
Role
President, R&D
Sold
93,456 shs ($1.58M)
Approx. gross sale proceeds
$1.58M
Approx. exercise cost
$385K
Approx. pre-tax spread
$1.20M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 93,456 | $0.00 | $0.00 |
| Exercise | Common Stock | 93,456 | $4.12 | $385K |
| Sale | Common Stock | 93,456 | $16.94 | $1.58M |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 contracts (Direct);
Common Stock — 418,557 shares (Direct)
Footnotes (4)
- F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.
- F2. Includes 15,037 shares underlying restricted stock units.
- F3. This transaction was executed in multiple trades at prices ranging from $16.15 to $17.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4. Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder vested in equal quarterly installments over the remaining thirty-six (36) months.
Key Figures
Options exercised: 93,456 shares
Option exercise price: $4.12 per share
Shares sold: 93,456 shares
+5 more
8 metrics
Options exercised
93,456 shares
Stock options exercised for common stock on June 22, 2026
Option exercise price
$4.12 per share
Exercise price for 93,456 stock options
Shares sold
93,456 shares
Common shares sold on June 22, 2026 after option exercise
Weighted average sale price
$16.94 per share
Weighted average price for shares sold in trades from $16.15 to $17.39
Post-transaction holdings
418,557 shares
Direct common stock holdings after reported transactions
Restricted stock units
15,037 shares
Shares underlying restricted stock units included in holdings
Option expiration date
April 9, 2028
Expiration date of the exercised stock option
Rule 10b5-1 adoption date
October 30, 2025
Adoption date of the trading plan governing the reported transaction
Key Terms
Rule 10b5-1 trading plan, restricted stock units, weighted average sale price, Stock Option (Right to Buy)
4 terms
Rule 10b5-1 trading plan regulatory
"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units financial
"Includes 15,037 shares underlying restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Relay Therapeutics (RLAY) report for Donald Bergstrom?
Relay Therapeutics reported that President, R&D Donald Bergstrom exercised 93,456 stock options at $4.12 per share and sold 93,456 common shares on June 22, 2026, as part of a planned Rule 10b5-1 trading program.
What stock options in Relay Therapeutics (RLAY) did Donald Bergstrom exercise?
He exercised a stock option for 93,456 shares of Relay Therapeutics common stock at an exercise price of $4.12 per share. The option was fully vested, with an expiration date of April 9, 2028, and now shows no remaining balance.
What vesting terms applied to the exercised Relay Therapeutics (RLAY) option?
The exercised option vested 25% on April 2, 2019, with the remaining shares vesting in equal quarterly installments over the next 36 months, meaning the entire 93,456-share grant was fully vested before Bergstroms June 22, 2026 exercise.
AI-generated analysis. How Rhea-AI works. Not financial advice.
